Elan Outlines Options For Tysabri If Biogen Idec Is Sold
This article was originally published in The Pink Sheet Daily
Larger pharmas, including Pfizer and Johnson & Johnson, are likely among the potential acquirers.
You may also be interested in...
Activist investor Carl Icahn is among those interested in the biotech.
The highly restricted Tysabri risk management program tipped the risk-benefit scale in Biogen Idec/Elan’s favor.
Biogen CFO predicts favorable reimbursement for natalizumab, minimizing cost for most patients.